|
|
Post by mnholdem on Mar 25, 2017 17:59:12 GMT -5
Have you checked out GoodRx lately? In their drug description, they don't even mention that Afrezza is inhaled...only that it's an expensive drug that's less popular than comparable drugs. Excerpt:
Afrezza (insulin) is an expensive drug used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There are currently no generic options for any insulin brand, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. Compare insulins.
Source: www.goodrx.com/afrezza?form=titration-pack&dosage=180-cartridges-of-4-units-and-8-units&quantity=&days_supply=&label_override=AfrezzaThen check out comparable pricing for the titration pack. |
|
|
|
Post by peppy on Mar 25, 2017 18:08:26 GMT -5
Have you checked out GoodRx lately? In their drug description, they don't even mention that Afrezza is inhaled...only that it's an expensive drug that's less popular than comparable drugs. Excerpt:
Afrezza (insulin) is an expensive drug used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There are currently no generic options for any insulin brand, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. Compare insulins.
Source: www.goodrx.com/afrezza?form=titration-pack&dosage=180-cartridges-of-4-units-and-8-units&quantity=&days_supply=&label_override=AfrezzaThen check out comparable pricing for the titration pack. A fortune. the 4,8,12 was unavailable.
Priceless ; www.screencast.com/t/8RCYp9rIBK
|
|
|
|
Post by mnholdem on Mar 25, 2017 18:22:49 GMT -5
Expensive and unpopular. MannKind's CEO and Board of Directors need to wake up. It seems almost criminal how they have priced Afrezza and it's, IMHO, a dishonor to Alfred E Mann. Especially now that we're learning that Afrezza works best when administered with two doses (at the beginning of the meal, followed by a second adjustment dose) the cost of this treatment at the current prices is outrageous.  |
|
|
|
Post by rockstarrick on Mar 25, 2017 18:46:29 GMT -5
Have you checked out GoodRx lately? In their drug description, they don't even mention that Afrezza is inhaled...only that it's an expensive drug that's less popular than comparable drugs. Excerpt:
Afrezza (insulin) is an expensive drug used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There are currently no generic options for any insulin brand, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. Compare insulins.
Source: www.goodrx.com/afrezza?form=titration-pack&dosage=180-cartridges-of-4-units-and-8-units&quantity=&days_supply=&label_override=AfrezzaThen check out comparable pricing for the titration pack. I tried to tweet link to both Mike and Mannkind, no go, tweeted to Charles, no go. never had a problem before ?? This is unbelievable to say the least. |
|
|
|
Post by cjm18 on Mar 25, 2017 18:53:28 GMT -5
Isn't this the price before insurance?
Novolog and humalog are expensive too.
The description of afrezza on the site needs to change.
|
|
|
|
Post by sportsrancho on Mar 25, 2017 19:28:20 GMT -5
Have you checked out GoodRx lately? In their drug description, they don't even mention that Afrezza is inhaled...only that it's an expensive drug that's less popular than comparable drugs. Excerpt:
Afrezza (insulin) is an expensive drug used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There are currently no generic options for any insulin brand, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. Compare insulins.
Source: www.goodrx.com/afrezza?form=titration-pack&dosage=180-cartridges-of-4-units-and-8-units&quantity=&days_supply=&label_override=AfrezzaThen check out comparable pricing for the titration pack. I tried to tweet link to both Mike and Mannkind, no go, tweeted to Charles, no go. never had a problem before ?? This is unbelievable to say the least. I just tried to Tweet it also. It won't do it. I'll try copying it and DM'ing. |
|
|
|
Post by sportsrancho on Mar 25, 2017 19:31:18 GMT -5
It said direct message failed? WTF
It's on ST. They will see it.
|
|
|
|
Post by rockstarrick on Mar 25, 2017 19:52:09 GMT -5
It said direct message failed? WTF It's on ST. They will see it. How could they not know this  very disappointed, the only FDA approved INHALED insulin and it isn't in the description !! what the hell was the Billion dollars spent on ?? |
|
|
|
Post by mnkdfann on Mar 25, 2017 20:09:53 GMT -5
Then check out comparable pricing for the titration pack. What GoodRx says about titration pack, 4, 8, and 12 units: Afrezza is not yet available Afrezza has been approved by the FDA, but isn't available in pharmacies yet. Drugs may be approved days, weeks, or months before they're launched, so we encourage you to check back. As soon as Afrezza is released, we'll have prices from a variety of pharmacies and other places where you can buy it. We also offer other information about Afrezza, including potential side effects, how to identify it, and recent news. |
|
|
|
Post by surplusvalue on Mar 25, 2017 21:21:14 GMT -5
Not surprising. Once again MNKD management will be reacting to this lack of information and misinformation in the market after the damage is already done. Hate to sound like a broken record but much of this type of thing could have been countered by emphasis on earlier systematic advertising before it had time to cast its shadow on the product . Hence management bears a lot of responsibility for this in not being proactive in this regard.
|
|
|
|
Post by alethea on Mar 27, 2017 10:07:01 GMT -5
Expensive and unpopular. MannKind's CEO and Board of Directors need to wake up. It seems almost criminal how they have priced Afrezza and it's, IMHO, a dishonor to Alfred E Mann. Especially now that we're learning that Afrezza works best when administered with two doses (at the beginning of the meal, followed by a second adjustment dose) the cost of this treatment at the current prices is outrageous. <img src="//storage.proboards.com/forum/images/smiley/superangry.png" alt=" " class="smile" contenteditable="false" text=" " ![]() It's beyond outrageous. It's stupid and moronic. Approved almost THREE years ago and still not selling 300 units per week. The insulin is MIRACULOUS. The price is incomprehensibly idiotic. LOWER the price you stupid, stupid sons-0-b*t*hes. |
|
|
|
Post by sluggobear on Mar 27, 2017 13:51:46 GMT -5
Expensive and unpopular. MannKind's CEO and Board of Directors need to wake up. It seems almost criminal how they have priced Afrezza and it's, IMHO, a dishonor to Alfred E Mann. Especially now that we're learning that Afrezza works best when administered with two doses (at the beginning of the meal, followed by a second adjustment dose) the cost of this treatment at the current prices is outrageous. <img src="//storage.proboards.com/forum/images/smiley/superangry.png" alt=" " class="smile" contenteditable="false" text=" " ![]() It's beyond outrageous. It's stupid and moronic. Approved almost THREE years ago and still not selling 300 units per week. The insulin is MIRACULOUS. The price is incomprehensibly idiotic. LOWER the price you stupid, stupid sons-0-b*t*hes. At this point they've waited too long. Just lowering the price and still hoping insurance covers some number of Rx won't save the company. As I've suggested for about 6 months now, they must make a Hail Mary play in basically giving it away and hoping that good press allows for a huge buzz among diabetics. If T1's could afford afrezza for 3-6 months that could drive awareness and interest. I think everyone is finally realizing any chance of success with the current approach faded long ago. |
|
|
|
Post by dreamboatcruise on Mar 27, 2017 14:08:14 GMT -5
It's beyond outrageous. It's stupid and moronic. Approved almost THREE years ago and still not selling 300 units per week. The insulin is MIRACULOUS. The price is incomprehensibly idiotic. LOWER the price you stupid, stupid sons-0-b*t*hes. At this point they've waited too long. Just lowering the price and still hoping insurance covers some number of Rx won't save the company. As I've suggested for about 6 months now, they must make a Hail Mary play in basically giving it away and hoping that good press allows for a huge buzz among diabetics. If T1's could afford afrezza for 3-6 months that could drive awareness and interest. I think everyone is finally realizing any chance of success with the current approach faded long ago. Which portion of the patient population are you looking to lower the price? The discount coupon brings the price down to $15 per month for many patients that have commercial insurance. Does that need to be even lower? Is it for Medicare patients that don't have coverage? Since Afrezza isn't covered at all by most Medicare the coupon would provide $150 discount. Perhaps that should be increased? We really know nothing about the price of Afrezza that the insurance companies pay as that is all done in secret. |
|
|
|
Post by sweedee79 on Mar 27, 2017 15:15:45 GMT -5
Expensive and unpopular. MannKind's CEO and Board of Directors need to wake up. It seems almost criminal how they have priced Afrezza and it's, IMHO, a dishonor to Alfred E Mann. Especially now that we're learning that Afrezza works best when administered with two doses (at the beginning of the meal, followed by a second adjustment dose) the cost of this treatment at the current prices is outrageous. <img class="smile" contenteditable="false" alt=" " src="//storage.proboards.com/forum/images/smiley/superangry.png" Not to mention the fact that many if not most T1s say they need up to 3Xs more Afrezza to get the low A1C numbers... unit for unit Afrezza is more expensive... added to that poor insurance coverage... docs that are uncooperative ... YES ... we are up against a lot and if management doesn't wake up pretty soon it will be too late.. |
|
|
|
Post by sweedee79 on Mar 27, 2017 15:23:43 GMT -5
At this point they've waited too long. Just lowering the price and still hoping insurance covers some number of Rx won't save the company. As I've suggested for about 6 months now, they must make a Hail Mary play in basically giving it away and hoping that good press allows for a huge buzz among diabetics. If T1's could afford afrezza for 3-6 months that could drive awareness and interest. I think everyone is finally realizing any chance of success with the current approach faded long ago. Which portion of the patient population are you looking to lower the price? The discount coupon brings the price down to $15 per month for many patients that have commercial insurance. Does that need to be even lower? Is it for Medicare patients that don't have coverage? Since Afrezza isn't covered at all by most Medicare the coupon would provide $150 discount. Perhaps that should be increased? We really know nothing about the price of Afrezza that the insurance companies pay as that is all done in secret. to my knowledge there is no coupon available for Medicare patients or any government funded programs .. am I wrong?? I read this on the site .. government funded programs such as Medicare patients aren't qualified to use the coupon and they get no discount. |
|
